Tech Review reports on a new study from the Journal of Clinical Oncology that provides a link between personalized medicine and better health outcomes. For the study, oncologist Lecia Sequist genetically screened patients' lung cancers and then administered a drug tailored for that type of tumor — and those patients did better than the average chemotherapy outcomes. In particular, the study looked at AstraZeneca's Iressa, an EGFR inhibitor. "This is a proof of concept," says Sequist. "We were trying to see if personalized medicine or genetically driven cancer therapy was feasible." AstraZeneca funded the trial.
Proof of Concept for Personalized Medicine
May 28, 2008